Targeted therapy for multiple myeloma

Seminars in Hematology

Volumn 38, Issue 3, 2001, Pages 286-294

  Anderson, Kenneth C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD20 ANTIGEN; CD40 ANTIGEN; CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 6; PHOSPHODIESTERASE IV INHIBITOR; PROTEASOME INHIBITOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANTIGEN SPECIFICITY; APOPTOSIS; CANCER SURVIVAL; CELL GROWTH; DNA DAMAGE; DNA STRAND BREAKAGE; GENE THERAPY; HUMAN; HUMAN HERPESVIRUS 8; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TARGET CELL; TUMOR IMMUNITY;

EID: 0034888319     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90021-6     Document Type: Article

References (100)

1. Allotransplants for mutliple myeloma
2. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
3. T cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Reduced transplant-related toxicity with preservation of graft versus myeloma effect
4. Novel biologically-based therapies for myeloma
5. Monoclonal antibody purged bone marrow transplantation therapy for multiple myeloma
6. Response of purified myeloma cells to hematopoietic growth factors
7. Strategies to improve the outcome of stem cell transplantation in multiple myeloma
8. Role of interleukin-6 in the growth of myeloma derived cell lines
9. Expression of vascular endothelial growth factor and its receptor in hematological malignancies
10. Apoptosis in multiple myeloma: Therapeutic implications
11. Cytokines and signal transduction in multiple myeloma
12. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays
13. Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells
14. Interleukin-6 inhibits Fas-induced apoptosis and SAP kinase activation in multiple myeloma cells
15. Oncostatin M induces association of GRB2 with Janus kinase JAK2 in multiple myeloma cells
16. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells
17. Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma
18. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism
19. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kB
20. RAFTK/PYK2-dependent and independent apoptosis in multiple myeloma cells
21. APAF-1 cytochrome-C independent and SMAC-dependent induction of apoptosis in multiple myeloma cells
22. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNFα
23. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
24. Thalidomide is an inhibitor of angiogenesis
25. Vascular endothelial growth factor and interleukin-6 in paracrine tumor stromal cell interactions in multiple myeloma
26. High producer haplotypes of tumor necrosis factor α and lymphotoxin are associated with an increased risk of myeloma and have an improved progression free survival after treatment
27. Novel therapeutic targets in multiple myeloma
28. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
29. Proteasome inhibition: A novel mechanism to combat asthma
30. Role of NFκB in the rescue of multiple myeloma cells from glucocorticoid induced apoptosis by Bcl-2
31. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells
32. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
33. Anti-CD38-blocked ricin: An immunotoxin for the treatment of multiple myeloma
34. Anti-B4 blocked ricin: A phase II trial of 7 day continuous infusion in patients with multiple myeloma
35. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor selection: Therapeutic applications
36. Multiple myeloma: Increasing evidence for a multistep transformation process
37. Proteasome inhibitor PS-341 is effective as a anti-angiogenic agent in the treatment of human pancreatic carcinoma via the inhibition of NFκB and subsequent inhibition of vascular endothelial growth factor production
38. + subsets
39. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
40. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy
41. Characterization of signaling cascades triggered by human IL-6 versus Kaposi's sarcoma associated herpesvirus encoded viral IL-6
42. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: Therapeutic applications
43. The proteasome inhibitor PS 341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
44. Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines
45. How proteolysis drives the cell cycle
46. NFκB regulates VCAM-1 expression on fibroblast-like synoviocytes
47. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
48. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma
49. p53 dependent induction of apopotosis by proteasome inhibitors
50. Targeting universal tumor antigens with cytotoxic T cells: Potential of CYP1B1 for broadly applicable antigen-specific immunotherapy
51. Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth
52. Interleukin-6 triggers cell growth via the ras dependent mitogen activated protein kinase (MAPK) cascade
53. Blockade of MAPK signaling in interleukin-6 independent multiple myeloma cells
54. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
55. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma
56. Changes in T cell receptor repertoire associated with graft-versus tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma receiving donor lymphocyte infusion
57. The ubiquitin proteasome pathway is required for processing the NFκB precursor protein and the activation of NFκB
58. Free radical mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
59. Lack of a role of interleukin-11 in the growth of multiple myeloma
60. Vascular endothelial growth factor triggered signaling cascades mediating multiple myeloma cell growth and migration
61. Thalidomide - A revival story
62. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences
63. Tumor cell/dendritic cell fusions as a vaccination strategy for myeloma
64. Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis
65. A multiple cytokine and second messenger responsive element in the enhancer of the human interleukin-6 gene: Similarities with c-fos gene regulation
66. The proteasome pathway is required for cytokine induced endothelial leukocyte adhesion molecule expression
67. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients
68. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
69. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma
70. Expression of interleukin-β and tumor necrosis factor α in plasma cells from patients with multiple myeloma
71. Combined immunotherapy with autologous adoptive tumor-specific T cell transfer and vaccination with CD40-activated leukemia cells for plasma cell leukemia
72. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma
73. Anti tumor activity of thalidomide in refractory multiple myeloma
74. + T cell depleted allogeneic bone marrow transplantation from genotypically HLA non-identical related donors
75. Prevention of graft-versus-host disease by selective depletion of CD6 positive T lymphocytes from donor bone marrow
76. + donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors
77. Purging of autologous peripheral blood stem cells using CD34 selection dose not improve overall or progression free survival following high dose chemotherapy for multiple myeloma: Results of a multi-center randomized controlled trial
78. Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage
79. The proteasome inhibitor PS-341 in cancer therapy
80. Adenovirus vector based purging of multiple myeloma cells
81. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines
82. The 86 kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells
83. CD20-directed antibody mediated immunotherapy induces responses and facilitates hematological recovery in patients with Waldentstrom's macroglobulinemia
84. The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders
85. Elevated soluble MUC-1 levels and decreased anti-MUC-1 antibody levels in patients with multiple myeloma
86. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B cell malignancies
87. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
88. Immunotherapeutic strategies for the treatment of plasma cell malignancies
89. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens
90. Immunoglobulin framework-derived peptides function as cytotoxic T cell epitopes expressed commonly in B cell malignancies
91. Characterization of adhesion molecules on human myeloma cell lines
92. Adhesion of human myeloma derived cell lines to bone marrow stromal cells stimulates IL-6 secretion
93. CD40 ligand triggered interleukin-6 secretion in multiple myeloma
94. The development of a model for the homing of multiple myeloma cells to human bone marrow
95. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein
96. Transforming growth factor β1: Differential effects on multiple myeloma versus normal B cells
97. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon in multiple myeloma cells
98. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
99. + selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma
100. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes